Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Previous studies using contrast-enhanced imaging for glioma isocitrate dehydrogenase (IDH) mutation assessment showed promising yet inconsistent results, and this study attempts to explore this problem by using an advanced tracer kinetic model, the distributed parameter model (DP). Fifty-five patients with glioma examined using dynamic contrast-enhanced imaging sequence at a 3.0 T scanner were retrospectively reviewed. The imaging data were processed using DP, yielding the following parameters: blood flow , permeability-surface area product PS, fractional volume of interstitial space , fractional volume of intravascular space , and extraction ratio . The results were compared with the Tofts model. The Wilcoxon test and boxplot were utilized for assessment of differences of model parameters between IDH-mutant and IDH-wildtype gliomas. Spearman correlation was employed to investigate the relationship between DP and Tofts parameters. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis and quantified using the area under the ROC curve (AUC). Results showed that IDH-mutant gliomas were significantly lower in ( = 0.018), PS ( < 0.001), ( < 0.001), ( < 0.001), and ( = 0.002) than IDH-wildtype gliomas. In differentiating IDH-mutant and IDH-wildtype gliomas, had the best performance (AUC = 0.92), and the AUCs of PS and were 0.82 and 0.80, respectively. In comparison, Tofts parameters were lower in ( = 0.013) and ( < 0.001) for IDH-mutant gliomas. No significant difference was observed in ep ( = 0.525). The AUCs of , , and ep were 0.69, 0.79, and 0.55, respectively. Tofts-derived showed a strong correlation with DP-derived ( > 0.9, < 0.001). showed a weak correlation with ( < 0.3,  > 0.16) and a very weak correlation with PS ( < 0.06,  > 0.8), both of which were not statistically significant. The findings by DP revealed a tissue environment with lower vascularity, lower vessel permeability, and lower blood flow in IDH-mutant than in IDH-wildtype gliomas, being hostile to cellular differentiation of oncogenic effects in IDH-mutated gliomas, which might help to explain the better outcomes in IDH-mutated glioma patients than in glioma patients of IDH-wildtype. The advantage of DP over Tofts in glioma DCE data analysis was demonstrated in terms of clearer elucidation of tissue microenvironment and better performance in IDH mutation assessment.